|Latest Earnings (Q3 ending 09/2021)||Upcoming Announcement (Q4 ending 12/2021)|
|Q3||-$0.02||Estimate increased in year|
leading up to announcement
|Q4 consensus estimate||-$0.03||Q4 consensus estimate is higher|
than previous yr's Q4 actual
|Q3 Consensus estimate||-$0.03||Previous year's Q4 actual||-$0.07|
BIOL's fiscal year ends in December
Information provided by Copyright © 2021. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.